

## Education and examination regulations BMS (OER)

### Testing regulations master - 2019-2020

#### – year 1

Testing regulations previous year 2018-2019

## 1 Testing regulations master year 1 - 2019-2020

- BMS01 Thinking critically about science
- BMS02 Management skills for a consultant
- BMS03 Policy research
- BMS04 Policy making, health sys. & public managm.
- BMS05 Participatory approaches to innovation
- BMS06 Science popularisation
- BMS07 Science, communication and society
- BMS08 Qualitative research
- BMS09 Science presentation and visualisation
- BMS10 Laboratory animal science
- BMS11 BROK
- BMS12 Research with ionising radiation
- BMS13 Data-analysis and modeling in MATLAB
- BMS14 Design and analysis of experiments
- BMS15 Big data in biomedical research
- BMS16 Causal inference in observation. research
- BMS17 Genetic association studies
- BMS18 Systematic reviews and meta-analyses
- BMS19 Vision: From molecule to percept & treatm.
- BMS20 Hearing: function, dysfunction & treatm.
- BMS21 Neurodevelopmental disorders: bench to bedside
- BMS22 Vanishing boundaries between neurodevelopmental disorders
- BMS23 Biomedical imaging: seeing is understanding
- BMS24 Introduction to neuroimaging 1
- BMS25 Introduction to neuroimaging 2
- BMS26 Neuroscience of sleep
- BMS27 Higher order cognition and emotion
- BMS28 Stress-related disorders
- BMS29 Experimental models of stress and (mal)adaptation

# BIOMEDICAL SCIENCES – TESTING REGULATIONS

---

- [BMS30 Animal mod. for psychiatric and neurological disorders](#)
- [BMS31 OMICS data analysis for systems biology](#)
- [BMS32 Molecular and cellular neuroscience](#)
- [BMS33 Neural stem cells to model neurological disorders](#)
- [BMS34 Reconstructive and regenerative medicine](#)
- [BMS37 Cell death in life and disease](#)
- [BMS38 Biomarkers: let's get personal](#)
- [BMS39 Understanding proteins in 3D](#)
- [BMS40 Nanomedicine](#)
- [BMS41 Advanced models of human disease](#)
- [BMS42 Targeting cellular processes to treat disease](#)
- [BMS43 From target to therapy](#)
- [BMS44 Mitochondrial disease drug development](#)
- [BMS45 Kidney in health and disease](#)
- [BMS46 Healthy versus neurodegener. brain aging](#)
- [BMS47 Biomarkers in population-based research](#)
- [BMS48 Clinical trials](#)
- [BMS49 Movement science in rehabilitation](#)
- [BMS50 Neural control of movement](#)
- [BMS51 Sensorimotor control](#)
- [BMS52 Disorders of movement](#)
- [BMS53 Orthopaedic biomechanics in motion](#)
- [BMS54 Applied exercise physiology](#)
- [BMS55 From vascular function to vascular fail.](#)
- [BMS56 Health outcome measurement](#)
- [BMS57 Health care improvement science](#)
- [BMS58 Cost-effectiveness analysis in health care](#)
- [BMS59 Prediction models in health science](#)

- [BMS60 Human risk assessment](#)
- [BMS61 Statistical modeling in observational research](#)
- [BMS62 Advanced modelling in economic evaluation](#)
- [BMS63 Biodynamic and toxicokinetic modeling](#)
- [BMS64 Molecular and cellular toxicology](#)
- [BMS65 Clinical toxicology](#)
- [BMS66 Reproductive epidemiology and toxicology](#)
- [BMS67 Chemical mutagenesis and carcinogenesis](#)
- [BMS68 Urological cancers](#)
- [BMS69 Tumors of the digestive tract](#)
- [BMS71 Women's cancers](#)
- [BMS72 Cancer development and immune defense](#)
- [BMS73 Infectious diseases and global health](#)
- [BMS74 Inflammatory diseases](#)
- [BMS75 Advanced tools in molecular biology](#)
- [BMS76 Cell movements](#)